Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01401699 · ClinicalTrials.gov registry record · NA

Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction

A NA study of Barrett's Esophagus, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
109
Enrollment target
1
Study location

NCT01401699 is a NA study of Barrett's Esophagus that has completed, run by Massachusetts General Hospital. The registered enrollment target is 109 participants, below the 519-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01401699, a NA study of Barrett's Esophagus, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
109 participants
Enrollment target
1
Study location

Study Summary

The specific aim of this study is to determine the accuracy of Optical Coherence Tomography (OCT) imaging for screening and diagnosis of the distal esophagus in patients undergoing a clinical esophagogastroduodenoscopy (EGD) procedure. The accuracy of results obtained using the developed OCT imaging probe will be determined and compared with those obtained through the traditional standard of care endoscopic biopsy .

Conditions Studied

Interventions

  • DEVICE Optical Frequency Domain Imaging (OFDI)

Study Locations (1)

Massachusetts

  • Massachussetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2006-09
Est. Completion 2011-11-16
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01401699

The ClinicalTrials.gov registry entry for NCT01401699 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 519-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (79% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Barrett's Esophagus appearing as the primary indexed condition, and to 1 intervention - of which Optical Frequency Domain Imaging (OFDI) is the first listed.

NCT01401699 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01401699 about?

NCT01401699 is a clinical study titled "Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction". The specific aim of this study is to determine the accuracy of Optical Coherence Tomography (OCT) imaging for screening and diagnosis of the distal esophagus in patients undergoing a clinical esophagogastroduodenoscopy (EGD) procedure. The accuracy of results obtained using the developed OCT imaging...

What is the current status of trial NCT01401699?

This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2006-09. Estimated completion is 2011-11-16.

What conditions does trial NCT01401699 study?

This clinical trial studies the following conditions: Barrett's Esophagus.

What interventions are being tested in trial NCT01401699?

The interventions under investigation include: Optical Frequency Domain Imaging (OFDI) (DEVICE).

Who is sponsoring clinical trial NCT01401699?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01401699 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett's Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.